PMC:7405836 / 110853-111091 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T183","span":{"begin":46,"end":56},"obj":"Chemical"}],"attributes":[{"id":"A183","pred":"chebi_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/CHEBI_6078"}],"text":"advantages that limit the clinical utility of ivermectin is its potential to cause cytotoxicity. However, altering the vehicles used in the formulations, the pharmacokinetic properties can be modified, thereby having significant control o"}

{"project":"LitCovid-PubTator","denotations":[{"id":"3042","span":{"begin":83,"end":95},"obj":"Disease"}],"attributes":[{"id":"A3042","pred":"tao:has_database_id","subj":"3042","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"advantages that limit the clinical utility of ivermectin is its potential to cause cytotoxicity. However, altering the vehicles used in the formulations, the pharmacokinetic properties can be modified, thereby having significant control o"}